SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001104659-23-054819
Filing Date
2023-05-02
Accepted
2023-05-02 08:26:53
Documents
6
Period of Report
2023-05-02

Document Format Files

Seq Description Document Type Size
1 PRE 14A tm232158d1_pre14a.htm PRE 14A 619972
2 GRAPHIC image_001.jpg GRAPHIC 4709
3 GRAPHIC image_002.jpg GRAPHIC 2070
4 GRAPHIC image_003.jpg GRAPHIC 5991
5 GRAPHIC tm232158d1_pre14aimg001.jpg GRAPHIC 112968
6 GRAPHIC tm232158d1_pre14aimg002.jpg GRAPHIC 266790
  Complete submission text file 0001104659-23-054819.txt   1153832
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-33357 | Film No.: 23876715
SIC: 2836 Biological Products, (No Diagnostic Substances)